Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.54% | 76.05% | -30.50% | -333.20% | 1.01% |
| Total Depreciation and Amortization | 5.61% | 6.15% | 7.89% | 7.91% | 3.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 216.44% | 111.38% | 84.11% | 410.05% | -201.04% |
| Change in Net Operating Assets | 165.29% | -204.57% | 44.96% | 27.09% | -290.27% |
| Cash from Operations | 40.81% | -573.02% | -4.85% | -609.79% | -92.57% |
| Capital Expenditure | 69.69% | 88.62% | -163.23% | 25.88% | -152.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.83% | 103.35% | -123.37% | 501.21% | 230.28% |
| Cash from Investing | -72.85% | 103.21% | -125.36% | 472.08% | 229.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | -88.36% | -100.00% | -76.07% | -- | 14.36% |
| Repurchase of Common Stock | 66.22% | -62.16% | 51.87% | -- | -124.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.97% | -100.06% | 101.92% | 99.23% | 117.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.73% | -265.05% | -1,968.27% | 225.15% | 154.67% |